Survivin plays a role in CD133+ cell chemoresistance to 5-fluorouracil (5-FU) in colon CSCs and a survivin inhibitor may be a new targeted agent to effectively treat CD133+ colon cancer [107]. This evidence concerns the gene BIRC5 and malignant colon neoplasm.